Papers/PMID:41859772
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.
Endocrinology, diabetes & metabolism2026The record
1 finding drawn from this paper, on 1 compound across 1 endpoint.
What it reported
How to read these marksWhat moved
1 finding
coenzyme Q10 — decreases fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The administration of CoQ10 resulted in a significant decrease in FBG levels (ESWMD = −5.04, 95% CI: −7.67, −2.40; p < 0.001, I 2 = 58.7%, p = 0.04) (Figure.”
Quoted verbatim from Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.. - Study
- meta-analysis
- Dose
- 110 to 376.6 mg/day CoQ10 across the included meta-analyses
- Population
- Adults with type 2 diabetes, obesity, polycystic ovary syndrome, chronic kidney disease, metabolic syndrome and other cardiometabolic conditions, from the randomised controlled trials pooled by eight meta-analyses.
Effect -5.04 mean difference, 95% CI -7.67 to -2.4
Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.2026PMID:41859772